<DOC>
	<DOCNO>NCT02866227</DOCNO>
	<brief_summary>This Phase II study design assess safety efficacy investigational product , TOL-463 , treat vaginitis .</brief_summary>
	<brief_title>TOL-463 Phase 2 Study</brief_title>
	<detailed_description>This Phase II randomize single blind safety efficacy study TOL-463 , administer female adult treat vaginitis . Participants randomly assign ( 1:1 ) dose TOL-463 Gel TOL-463 Insert . Study medication administer vaginally , nightly seven day . The duration study participant approximately 21-30 day .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<criteria>Participants eligible participate study must meet criterion 1 2 remain inclusion criterion : 1 . Diagnosis bacterial vaginosis base presence four Amsel criterion . * *Homogeneous vaginal discharge ( white , milky gray , thin ) , positive KOH whiff test , vaginal secretion pH &gt; 4.5 , clue cell &gt; /= 20 percent vaginal squamous epithelial cell saline `` wet mount '' 2 . Diagnosis VVC base presence pseudohyphae KOH preparation ; must also least one sign one symptom* , rat base severity** minimum composite score 2 . *Signs include vulvovaginal edema , erythema , and/or excoriation . Symptoms include vulvovaginal itching , burning , and/or irritation . **Severity grade scale 03 ( absent = 0 ; mild = 1 ; moderate = 2 ; severe = 3 ) . 3 . Participant willing able provide write informed consent . 4 . Participant 1850 year age . 5 . Participant general good health base medical history , physical examination , vital sign , pelvic examination . 6 . Documentation normal ASCUS HPV negative Pap test within prior 3 year . 7 . Participant must negative urine pregnancy test study enrollment . 8 . Participant must agree abstain sexual intercourse seven day study medication use . 9 . Participant must nonchildbearing potential* must use highly effective birth control** avoid become pregnant 30 day prior end study treatment . *Nonchildbearing potential define postmenopausal least 1 year , status bilateral tubal ligation least 1 year , status bilateral oophorectomy status hysterectomy . **Acceptable method birth control include use hormonal contraceptive abstinent vaginal sexual intercourse 30 day prior study drug dose agree abstain oral , anal , vaginal sexual intercourse study drug dosing , sexually active , use nonlubricated condom ( addition hormonal contraception ) remainder study final TOC visit . Intravaginal intrauterine contraceptive contraceptive device acceptable form birth control study . 10 . Participant willing able cooperate extent degree require protocol discretion investigator . 11 . Participant willing refrain douche apply intravaginal products/medications* throughout course trial . *e.g. , antifungal preparation , deodorant spray , spermicide , contraceptive cream , gel , foam , sponge 12 . Participant willing refrain use tampon diaphragms first seven day study . 1 . A diagnosis vaginitis BV VVC another vaginal vulvar condition* might confuse interpretation response study product . *Examples condition include erosive lichen planus , desquamative interstitial vaginitis , contact dermatitis involve vulvar epithelium . 2 . Presence T. vaginalis wet mount evidence infectious cause cervicitis vaginitis physical examination . 3 . Active genital lesion , include ulcer , vesicle consistent herpes , wart . 4 . Use metronidazole 5nitroimidazole derivative clindamycin antifungal agent ( intravaginal systemic ) treatment condition within 14 day start study . 5 . Planned ongoing immunosuppressive therapy systemic antibiotic treatment course study . 6 . Use investigational drug within 30 day prior screen . 7 . History hypersensitivity ingredient formulation . 8 . Women cervical intraepithelial neoplasia ( CIN ) cervical carcinoma . 9 . Currently breastfeed . 10 . Menstruating time diagnosis . * *Women menstruate time diagnosis may rescreened late time . 11 . Any condition , opinion investigator , would interfere participation study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>TOL-463 , Vaginal , Gel , Insert , Vaginitis , Bacterial , Vaginoses , Vulvovaginal , Candidiasis</keyword>
</DOC>